Although the association of cancer and venous thromboembolism is well known, little data is available on the occurrence of ATE in patients with malignant tumours [1]. Thus, Dr Frits Mulder (Amsterdam UMC, University of Amsterdam, the Netherlands) and colleagues set out to evaluate the risk of ATE in cancer patients versus the general population.
The analysis included registry data from a cohort of 458,462 adult patients with a first-time cancer diagnosis between 1997 and 2017 and 1,375,386 participants from the general population matched by sex and age Median age was 69 years for both groups. Primary outcome was the assessment of ATE consisting of a composite of myocardial infarction, stroke (i.e. ischaemic or unspecified), and peripheral artery occlusion. At 6 and 12 months of the study, cumulative incidences were calculated per 1,000 person-years and cause-specific hazard ratios for ATE were assessed between groups by using a Cox regression model.
At 6 and 12 months, the cumulative incidences of ATE were 1.50% and 2.11% in the cancer patient group, while ATE was found in 0.76% and 1.48% of the general population cohort, respectively. Hazard ratios were 2.36 (6 months) and 1.87 (12 months). There were substantial risk differences depending on age and type of cancer, with higher incidences of ATE in patients over 75 years with e.g. brain, pancreas, stomach, lung, and bladder cancers and lower incidences in patients under 65 with breast, prostate, and gynaecological cancers (see Figure).
Figure: ATE incidence rate for each cancer type during the first 6 months after cancer diagnosis [1]
Per 1,000 person-years with 95% confidence interval.
Posted on
Previous Article
« Residual pulmonary obstruction may predict risk of VTE recurrence Next Article
Factor V Leiden mutation linked to atrial fibrillation »
« Residual pulmonary obstruction may predict risk of VTE recurrence Next Article
Factor V Leiden mutation linked to atrial fibrillation »
Table of Contents: ISTH 2020
Featured articles
Haemophilia and Rare Bleeding Disorders
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
What’s New in Anticoagulation
Finding the sweet spot of anticoagulation in AF patients with ACS
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
COVID-19 and Thrombosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
What’s New in Venous Thromboembolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Less diagnostic delay in CTEPH diagnosis with novel algorithm
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Pearls of the Posters
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Physical rehabilitation improves health outcomes after pulmonary embolism
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients
Factor V Leiden mutation linked to atrial fibrillation
Increased rates of arterial thromboembolism in cancer patients
Related Articles
September 8, 2020
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com